- Home
- PLPC vs BCYC Comparison
PLPC vs BCYC Comparison
Compare PLPC & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLPC
- BCYC
- Stock Information
- Founded
- PLPC 1947
- BCYC 2009
- Country
- PLPC United States
- BCYC United Kingdom
- Employees
- PLPC N/A
- BCYC N/A
- Industry
- PLPC Water Sewer Pipeline Comm & Power Line Construction
- BCYC Biotechnology: Pharmaceutical Preparations
- Sector
- PLPC Industrials
- BCYC Health Care
- Exchange
- PLPC Nasdaq
- BCYC Nasdaq
- Market Cap
- PLPC 670.0M
- BCYC 566.5M
- IPO Year
- PLPC N/A
- BCYC 2019
- Fundamental
- Price
- PLPC $153.54
- BCYC $7.42
- Analyst Decision
- PLPC
- BCYC Buy
- Analyst Count
- PLPC 0
- BCYC 10
- Target Price
- PLPC N/A
- BCYC $25.00
- AVG Volume (30 Days)
- PLPC 123.3K
- BCYC 223.0K
- Earning Date
- PLPC 07-30-2025
- BCYC 08-05-2025
- Dividend Yield
- PLPC 0.51%
- BCYC N/A
- EPS Growth
- PLPC N/A
- BCYC N/A
- EPS
- PLPC 7.89
- BCYC N/A
- Revenue
- PLPC $601,351,000.00
- BCYC $25,722,000.00
- Revenue This Year
- PLPC N/A
- BCYC $7.35
- Revenue Next Year
- PLPC N/A
- BCYC N/A
- P/E Ratio
- PLPC $19.71
- BCYC N/A
- Revenue Growth
- PLPC N/A
- BCYC N/A
- 52 Week Low
- PLPC $109.01
- BCYC $6.10
- 52 Week High
- PLPC $159.05
- BCYC $28.67
- Technical
- Relative Strength Index (RSI)
- PLPC 61.19
- BCYC 36.14
- Support Level
- PLPC $152.07
- BCYC $8.33
- Resistance Level
- PLPC $155.29
- BCYC $8.63
- Average True Range (ATR)
- PLPC 3.77
- BCYC 0.50
- MACD
- PLPC 0.58
- BCYC -0.13
- Stochastic Oscillator
- PLPC 76.21
- BCYC 7.18
About PLPC Preformed Line Products Company
Preformed Line Products Co is a designer and manufacturer of products and systems for constructing and maintaining overhead and underground networks for energy, telecommunication, cable operators, data communication, and other industries. In addition, it provides solar hardware systems and mounting hardware for a variety of solar power applications. Its products consist of Energy Products, Communications Products, and Special Industries Products. The company's majority of the revenue is derived from the sale of products in The Americas with operations also in PLP-USA, Europe, the Middle East and Africa, and Asia-Pacific. The revenue gets driven by Energy products which comprise protecting transmission conductors, spacers, spacer-dampers, and Stockbridge dampers.
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.